Pharma Journalist -

Moderna, Inc., announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against COVID-19. mRNA-1273 is Moderna’s second mRNA…
Read More...

Xencor, Inc. and Atreca, Inc. announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific…
Read More...

Concert Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543,…
Read More...

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that LYNPARZA has been approved in the European Union (EU) as a monotherapy for the maintenance…
Read More...

Corvus Pharmaceuticals, Inc. announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. The first cohort of five patients…
Read More...

Turning Point Therapeutics, Inc. and Zai Lab announced an exclusive license agreement for the development and commercialization of Turning Point’s lead drug candidate, repotrectinib, in…
Read More...

The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75…
Read More...

Novavax, Inc. announced that it has been selected to participate in Operation Warp Speed (OWS), a U.S. government program that aims to begin delivering millions of doses of a safe,…
Read More...

GSK and Medicago announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s…
Read More...

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, announced it has raised $110 million in a Series B financing.…
Read More...